FDA Approval: Panitumumab (Vectibix) for Colorectal Cancer

A doorbell, and the wire behind it

The epidermal growth factor receptor, or EGFR, sits on the outside of cells. When a growth signal binds to it, the receptor passes the message inward and the cell is told to grow and divide. Colon and rectal cancers often carry too many of these receptors.

Panitumumab is a monoclonal antibody that plugs the receptor. Nothing can bind it, so the doorbell never rings.

Now the catch. The message from EGFR travels down a wire made of proteins called KRAS and NRAS, known together as RAS. In some tumors RAS is mutated and stuck in the on position. Then the wire is live whether or not the doorbell works, and blocking the receptor achieves nothing.

That is why the drug was later restricted rather than expanded. Its usefulness was never about the drug alone.

The test comes before the prescription

The label now covers adults with wild-type RAS metastatic colorectal cancer. Wild-type means no mutation in either KRAS or NRAS. An FDA-approved test has to show that.

It states the limits directly. Panitumumab is not indicated for RAS-mutant disease, except in one narrow combination. And it is not indicated when RAS status is unknown.

That second clause is unusual and worth pausing on. Not knowing is treated the same as a positive mutation. The reason sits in the safety section. Across randomized trials, giving an anti-EGFR antibody to people with RAS-mutant tumors brought the side effects and no benefit. In the first-line FOLFOX trial, 548 people turned out to have RAS-mutant tumors. In an exploratory look at that group, overall survival was shorter when panitumumab was added. The hazard ratio was 1.21.

A drug that helps one group and harms another is the clearest possible argument for testing first. Our page on biomarker testing covers how that testing is done.

There is one exception on the current label. With sotorasib, panitumumab is indicated for KRAS G12C-mutated disease after prior chemotherapy, because sotorasib blocks that specific mutant protein directly.

What the 2006 evidence actually showed

The original approval came from Study 20020408. It was an open-label randomized trial in 463 people. All had cancer that had already progressed through fluoropyrimidine, oxaliplatin and irinotecan chemotherapy. Half got panitumumab plus best supportive care. Half got supportive care alone.

Progression-free survival improved: a mean of 96 days against 60 days. When the tumors were tested afterwards, the benefit sat in the wild-type KRAS group, where the hazard ratio was 0.45. Response rate was 17% with panitumumab and 0% without.

There was no difference in overall survival. The label gives the reason: 77% of the supportive-care group went on to receive panitumumab when their disease progressed, which blurs any survival comparison.

Moving to first-line treatment

Study 20050203 tested panitumumab added to FOLFOX chemotherapy as the first treatment for metastatic disease. FOLFOX combines oxaliplatin, leucovorin and fluorouracil. Our page on chemotherapy explains how such combinations are built.

In the wild-type RAS group, median progression-free survival was 10.1 months with panitumumab plus FOLFOX and 7.9 months with FOLFOX alone. Median overall survival was 25.8 months against 20.2 months, a hazard ratio of 0.77. Tumors responded in 58% against 45%.

It is given by vein every 14 days, over about an hour to an hour and a half, with the amount worked out from body weight by the treating team.

The rash is the point, not a footnote

Panitumumab's boxed warning is for skin toxicity. EGFR is not only on tumors; it is also on normal skin and hair follicles. Blocking it there causes trouble.

Skin reactions occurred in 90% of patients on the drug alone, severe in 15%. With FOLFOX the figure was 96%, severe in 32%. The rash is acne-like, with itching, redness, peeling, dry skin, cracked skin and infected nail folds.

The label warns that these areas can become seriously infected, and instructs teams to monitor for that. It also advises limiting sun exposure.

Other warnings cover low blood magnesium and other salts, which need monitoring. There are also warnings for infusion reactions, lung scarring, and eye problems.

When to get checked

Panitumumab treats cancer that has already spread. Most colorectal cancer is found earlier, and screening is why. NCI lists symptoms worth a doctor's visit:

• Blood in the stool, bright red or very dark.
• A change in bowel habits, including new diarrhea or constipation.
• A feeling that the bowel does not empty completely.
• Stools that are narrower than usual.
• Ongoing gas pain, bloating, fullness or cramps.
• Weight loss for no known reason, fatigue, or vomiting.

Screening matters more than symptoms here. Polyps and early cancers usually cause no symptoms at all. The US Preventive Services Task Force recommends screening every adult aged 45 to 75. Our page on colonoscopy sets out what the test involves.

The wider numbers

For 2026 the American Cancer Society projects about 158,850 new colorectal cancers and about 55,230 deaths in the United States. Five-year relative survival for 2016 to 2022 was 65.4%, and the median age at diagnosis is 66.

By stage, five-year relative survival is 91.3% for localized disease, 75.2% for regional spread and 16.9% for distant disease. Distant disease accounts for 23% of diagnoses, and that is the group panitumumab is for. These are population figures and describe no individual.

What this approval cannot tell you

It cannot tell you the drug will help a given person. Without wild-type RAS it will not, and the label says so.

It cannot promise longer life in the refractory setting. That trial showed delayed progression, not longer survival, for reasons the label explains.

And an approval from 2006 is not a snapshot that holds. This label has been narrowed by biomarker, widened by a new combination, and revised again in 2025. The current prescribing information, not the original news story, is what governs care.

Sources

• DailyMed, VECTIBIX (panitumumab) injection prescribing information, revised January 2025 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2
• NCI PDQ, Colon Cancer Treatment (Patient Version) — https://www.cancer.gov/types/colorectal/patient/colon-treatment-pdq
• US Preventive Services Task Force, Colorectal Cancer: Screening — https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening
• SEER Cancer Stat Facts, Colorectal Cancer — https://seer.cancer.gov/statfacts/html/colorect.html

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.